Snell & Wilmer advised Brenig Therapeutics, Inc. on the transaction. Brenig Therapeutics, Inc. (“Brenig”) announced it secured $65 million in Series A financing led by New...
You must be a Standard 1 Year member to access this content.
Snell & Wilmer represented Trawsfynydd Therapeutics, Inc. in the transaction, and Orrick, Herrington & Sutcliffe and Morgan, Lewis & Bockiu represented David Schulman. Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”)...
You must be a Standard 1 Year member to access this content.
Snell & Wilmer advised A.O. Reed & Co. on the transaction. An Energy Transition Accelerator™ Legence announced its acquisition of A.O. Reed & Co. With the addition of...
You must be a Standard 1 Year member to access this content.
